Garvin Chandler, DO
Family Medicine · Rome, GANPI 1073963492
Payments from drug & device makers
Across 143 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$494
- Pfizer$390
- AbbVie$311
- Phathom Pharmaceuticals, Inc.$239
- Lilly USA, LLC$201
- Astellas Pharma US Inc$129
- plus $768 from 14 others
What the payments were for
- Food & beverage$2,520100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $494 |
| Pfizer | 24 | $390 |
| AbbVie | 22 | $311 |
| Phathom Pharmaceuticals, Inc. | 8 | $239 |
| Lilly USA, LLC | 11 | $201 |
| Astellas Pharma US Inc | 6 | $129 |
| Amgen | 6 | $106 |
| AstraZeneca | 7 | $105 |
| Otsuka America Pharmaceutical, Inc. | 3 | $88 |
| Xeris Pharmaceuticals, Inc. | 5 | $87 |
| Exact Sciences | 5 | $84 |
| GSK | 5 | $78 |
| Boehringer Ingelheim | 2 | $58 |
| Bayer | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Cequr Corporation | 1 | $17 |
| Merck | 1 | $16 |
| Medtronic | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$121
How this compares
$2,532 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $93,605 |
| EliquisApixaban | 87 | $82,928 |
| MounjaroTirzepatide | 40 | $71,887 |
| JardianceEmpagliflozin | 45 | $41,997 |
| XareltoRivaroxaban | 45 | $41,688 |
| TrulicityDulaglutide | 18 | $33,117 |
| FarxigaDapagliflozin Propanediol | 29 | $27,836 |
| MyrbetriqMirabegron | 27 | $24,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $23,502 |
| LinzessLinaclotide | 29 | $22,675 |
| Repatha SureclickEvolocumab | 16 | $12,093 |
| QuviviqDaridorexant Hcl | 21 | $9,418 |
| VoqueznaVonoprazan Fumarate | 13 | $8,697 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 145 | $4,140 |
| Atorvastatin Calcium | 503 | $3,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $201 | $106,99774 claims |
| Novo NordiskOzempic | $494 | $93,60580 claims |
| PfizerEliquis, Paxlovid | $390 | $85,78698 claims |
| Boehringer IngelheimJardiance | $58 | $41,99745 claims |
| AstraZenecaFarxiga, Symbicort | $105 | $31,24844 claims |
| AbbVieLinzess, Synthroid | $311 | $25,61953 claims |
| Astellas Pharma US IncMyrbetriq | $129 | $24,50327 claims |
| GSKTrelegy Ellipta | $78 | $23,50226 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $239 | $8,69713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Rome
- Anne WhiteRome$124K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.